Article

Targeting device therapy: genomics of sudden death.

Division of Cardiology, Cardiovascular Institute, University of Pittsburgh Medical Center, Scaife S-572, 200 Lothrop Street, Pittsburgh, PA 15213-2582, USA.
Heart Failure Clinics (Impact Factor: 1.41). 01/2010; 6(1):93-100. DOI: 10.1016/j.hfc.2009.08.005
Source: PubMed

ABSTRACT This article discusses the development and use of genomic predictors to define the population at risk for sudden cardiac death, which is usually defined as death from cardiac causes within an hour of symptom onset. The identification of genetic predictors of sudden death in heart failure is in its earliest stages. Mutations in ion channels have been shown to cause inherited forms of sudden death; there is, however, little evidence that mutations or rare single nucleotide polymorphisms (SNPs) in those genes are important causes of the common forms of sudden death. Other common variants in ion channels and related genes are associated with sudden death in the setting of acute myocardial infarction or heart failure. Ultimately, we hope to identify a handful of SNPs that modulate the risk of sudden death in heart failure and to develop an algorithm to predict risk based on genotype.

1 Bookmark
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Implantable cardioverter-defibrillators (ICDs) constitute an effective therapy for protection against death in survivors of sudden cardiac arrest and in those at risk for sudden cardiac death based on poor left ventricular function. In this article, the authors discuss the totally subcutaneous ICD (SC-ICD) system that was designed to provide an alternative to transvenous electrodes in patients who do not require cardiac pacing. The authors also discuss the promises and shortcomings of this new device technology compared with the conventional transvenous implantable defibrillator system and review the experience up-to-date with the SC-ICD.
    Cardiac electrophysiology clinics 09/2011; 3(3):403-408.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacogenomics explores one drug's varying effects on different patient genotypes. A better understanding of genomic variation's contribution to drug response can impact 4 arenas in heart failure (HF): (1) identification of patients most likely to receive benefit from therapy, (2) risk stratify patients for risk of adverse events, (3) optimize dosing of drugs, and (4) steer future clinical trial design and drug development. In this review, the authors explore the potential applications of pharmacogenomics in patients with HF in the context of these categories.
    Heart Failure Clinics 10/2014; · 1.41 Impact Factor
  • Source
    J. clin. exp. cardiol., 2012, vol. 2, spec. iss. , str. 1-7. 01/2012; 2:1-7.

Preview

Download
0 Downloads
Available from